Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Shareholder Voting Results

The Shareholders voted on the following matters at this year’s Meeting.

Proposal 1 – Election of Directors

The nominees listed in Zymework’s Management Information Circular dated May 2, 2018 (the “Circular”) were elected as Directors of the Company. Detailed results of the votes are set out below:

Proposal 2 – Appointment of Auditors

The vote was carried for the Appointment of the Auditors, KPMG LLP. Detailed results of the votes are set out below:

Proposal 3 – Amendment and Restatement of Stock Option Plan

The vote was carried on the resolution approving the proposed amendments to Zymeworks’ stock option plan, as more particularly described in the Circular. Detailed results of the votes are set out below:

Proposal 4 – Amendment and Restatement of Employee Stock Purchase Plan

The vote was carried on the resolution approving the proposed amendments to Zymeworks’ employee stock purchase plan, as more particularly described in the Circular. Detailed results of the votes are set out below:

Full details of all proposals are fully described in the Circular available on the Company’s profile on SEDAR at www.sedar.com, and on EDGAR at www.sec.gov, and the detailed results of voting on each proposal are included in the Report of Voting Results filed on SEDAR and on EDGAR.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. The company’s second product candidate, ZW49, capitalizes on the unique design and antibody framework of ZW25 and is a bispecific antibody-drug conjugate, or ADC, armed with the company’s proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180607006346/en/